系统性综述干细胞来源的生物材料采集的供者健康风险
作者简介:
通讯作者: 薛迪(1960-)，女，博士，教授，研究方向：卫生技术评估、医院管理。E-mail：xuedi@shmu.edu.cn
Systematic Review of the Donors' Health Risks of Biomaterial Collection to Stem Cell Providers
-
摘要: 通过检索国内外6个文献数据库以获取发表于2010年1月~2020年7月研究相关的文献，并对干细胞来源的生物材料采集的供者健康风险进行了系统性综述。50篇相关文献分析显示，在许多情况下，生物材料采集可使供者承受健康风险，包括麻醉、粒细胞集落刺激因子或促排卵药物使用、中心静脉导管放置、穿刺等带来的风险。此外，生物材料采集还可影响供者的心理健康。根据上述发现，建议干细胞来源的生物材料采集需要严格的伦理管控，以保障生物材料供者的健康权益。Abstract: Six literature databases in China and abroad were searched to obtain relevant literatures published from January 2010 to July 2020, and a systematic review was conducted to analyze the health risks of biomaterial collection to the persons who provided biomaterial as source of stem cells. After analyzing 50 literatures on the health risks of biomaterial providers, the study found biomaterial collection may leave the biomaterial providers potential health risks in many cases. Potential risks were caused by anaesthesia, granulocyte colony stimulating factor, ovulation induction drugs, placement of central venous catheter, bone marrow aspirations and others. In addition, biomaterial collection may also affect mental health of the providers. According to the study findings, the authors suggested that biomaterial collection as sources of stem cells should be strictly and ethically controlled to ensure the health right of biomaterial providers.
-
Keywords:
- stem cell /
- biomaterial /
- provider /
- health
-
-
表 1 干细胞来源的生物材料供者健康风险的文献发表年份
文献发表年份 文献数 百分比/% 2010年 3 6.00 2011年 5 10.00 2012年 3 6.00 2013年 9 18.00 2014年 7 14.00 2015年 13 26.00 2016年 2 4.00 2017年 2 4.00 2018年 4 8.00 2020年 2 4.00 合计 50 100.00 
下载: 导出CSV
表 2 干细胞来源的生物材料供者健康风险的文献作者国别
第一作者所在国家 文献数 百分比/% 中国 35 70.00 美国 2 4.00 西班牙 2 4.00 其他 11 22.00 合计 50 100.00
下载: 导出CSV
表 3 干细胞来源的生物材料供者健康风险的文献类型
文献类型 文献数 百分比/% 原始研究 3 6.00 系统性综述 2 4.00 学位论文 9 18.00 评述或一般综述 36 72.00 合计 50 100.00
下载: 导出CSV
-
[1] PERA M F, TAM P P L. Extrinsic regulation of pluripotent stem cells[J]. Nature, 2010, 465(7299): 713-720. doi: 10.1038/nature09228
[2] BITAN M, VAN WALRAVEN S M, WOREL N, et al. Determination of Eligibility in Related Pediatric Hematopoietic Cell Donors: Ethical and Clinical Considerations: Recommendations from a Working Group of the Worldwide Network for Blood and Marrow Transplantation Association[J]. Biol Blood Marrow Transplant, 2016, 22(1): 96-103. doi: 10.1016/j.bbmt.2015.08.017
[3] BOWEN J E. Technical Issues in Harvesting and Concentrating Stem Cells: Bone Marrow and Adipose[J]. PM R, 2015, 7(4 Suppl): S8-S18.
[4] RIEZZO I, PASCALE N, LA RUSSA R, et al. Donor Selection for Allogenic Hemopoietic Stem Cell Transplantation: Clinical and Ethical Considerations[EB/OL]. (2017-06-07)[2021-12-11]https://doi.org/10.1155/2017/5250790.
[5] PAHNKE S, FISCHERNIELSEN A, HAASTRUP E, et al. Differences in Side Effects, Sick Leave and the Will to Donate Again: The Nordic Register of Haematopoietic Stem Cell Donors[J]. Bone Marrow Transplant, 2016, 51(Suppl 1): S328-S329.
[6] MOALIC-ALLAIN V. Medical and ethical considerations on hematopoietic stem cells mobilization for healthy donors[J]. Transfus Clin Biol, 2018, 25(2): 136-143. doi: 10.1016/j.tracli.2018.02.004
[7] BOSI A, BARTOLOZZI B. Safety of bone marrow stem cell donation: A review[J]. Transplant Proc, 2010, 42(6): 2192-2194. doi: 10.1016/j.transproceed.2010.05.029
[8] BENDORF A, KERRIDGE I H. Ethical issues in bone marrow transplantation in children[J]. J Paediatr Child Health, 2011, 47(9): 614-619. doi: 10.1111/j.1440-1754.2011.02165.x
[9] 李建会. 从黄禹锡事件看伦理学对科学的重要性[J]. 医学与哲学: 人文社会医学版, 2006, 27(2): 14-18. https://www.cnki.com.cn/Article/CJFDTOTAL-YXZX200602005.htm
[10] 高敏芝, 汪玉宝. 卵巢过度刺激综合征的研究进展[J]. 生殖与避孕, 2005, 25(1): 41-45. https://www.cnki.com.cn/Article/CJFDTOTAL-SZBB200501009.htm
[11] 胡琳莉, 黄国宁, 孙海翔, 等. 促排卵药物使用规范: 2016[J]. 生殖医学杂志, 2017, 26(4): 302-307. doi: 10.3969/j.issn.1004-3845.2017.04.002